Moreover, in CML novel splicing events have been identified in transcripts of other genes involved in the regulation of hematopoietic development and cell fate determination (Ikaros) [39], in cell growth and senescence factors (Gfi1b, hTERT) [40, 41], and even in BCR-ABL itself, an event which may contribute to imatinib resistance [42]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.